Zolpimist is owned by Aytu.
Zolpimist contains Zolpidem Tartrate.
Zolpimist has a total of 1 drug patent out of which 0 drug patents have expired.
Zolpimist was authorised for market use on 19 December, 2008.
Zolpimist is available in spray, metered;oral dosage forms.
Zolpimist can be used as treatment of transient insomnia.
The generics of Zolpimist are possible to be released after 07 August, 2032.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8236285 | AYTU | Buccal, polar and non-polar spray containing zolpidem |
Aug, 2032
(9 years from now) |
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 19 December, 2008
Treatment: Treatment of transient insomnia
Dosage: SPRAY, METERED;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic